Quiditene | CAS# 57734-76-6 | H2 Receptor blocker

MedKoo Cat#: 412302 | Name: Quiditene

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Quiditene is a biochemical with antiulcer activity and serves as an H2 receptor blocker.

Chemical Structure

Quiditene

CAS#57734-76-6

Theoretical Analysis

MedKoo Cat#: 412302

Name: Quiditene

CAS#: 57734-76-6

Chemical Formula: C16H20ClNOS2

Exact Mass: 341.0675

Molecular Weight: 341.91

Elemental Analysis: C, 56.21; H, 5.90; Cl, 10.37; N, 4.10; O, 4.68; S, 18.75

Price and Availability

Size	Price	Availability	Quantity
500mg	USD 600.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Quiditene

IUPAC/Chemical Name

1-Azabicyclo(2.2.2)octane-3-methanol, alpha,alpha-di-2-thienyl-, hydrochloride (9CI)

InChi Key

YAUMMUPYNHXDND-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H19NOS2.ClH/c18-16(14-3-1-9-19-14,15-4-2-10-20-15)13-11-17-7-5-12(13)6-8-17;/h1-4,9-10,12-13,18H,5-8,11H2;1H

SMILES Code

OC(C1=CC=CS1)(C2=CC=CS2)C3CN4CCC3CC4.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

TBD

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Quiditene is a biochemical with antiulcer activity.

In vitro activity:

Quiditene-(qunuclidyl-3)-di-(thyenel-2)carbinole hydrochloride was studied by using various experimental models. The agent was compared with H2-blockers. When gastrically used, quiditene in doses of 5-50 mg/kg dose-dependently decreased gastric acid secretion and prevented acute gastric mucosal lesions. As cimetidine and ranitidine, the agent accelerated chronic gastric ulcer healing. Quiditene has been allowed for clinical studies in Russia. Reference: Eksp Klin Farmakol. 1994 Nov-Dec;57(6):36-8. Russian. https://pubmed.ncbi.nlm.nih.gov/7756958/

In vivo activity:

Study of anti-ulcer acftivity revealed that quiditene metabolites tdo not precent the gastrotoxic effects of histamine, absolute ethanol, and indomethacin on the mucous membrane of the stomach in rats; they do not have an anti-ulcerogenic effect. Quiditene revealed a pronounce anti-ulcer effect. Reference: Pharmaceutical Chemistry Journal, 29(1), 26–29.

	Solvent	mg/mL	mM
Solubility
	TBD	0.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 341.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kaminka ME, Tupikina SM, Mashkovskiĭ MD. Eksperimental'noe issledovanie antisekretornoĭ i protivoiazvennoĭ aktivnosti kviditena [An experimental study of the antisecretory and antiulcer activities of kviditen]. Eksp Klin Farmakol. 1994 Nov-Dec;57(6):36-8. Russian. PMID: 7756958. 2. Kuleshova, E. F., Anisimova, O. S., Sheinker, Y. N., Tupikina, S. M., Kaminka, M. É., Polikarpov, M. V., … Yakhontov, L. N. (1995). Study of the metabolism of the new anti-ulcer drug quiditene [(3-quinuclidyl)-di(2-thienyl)carbinol]. Pharmaceutical Chemistry Journal, 29(1), 26–29.

In vitro protocol:

Kaminka ME, Tupikina SM, Mashkovskiĭ MD. Eksperimental'noe issledovanie antisekretornoĭ i protivoiazvennoĭ aktivnosti kviditena [An experimental study of the antisecretory and antiulcer activities of kviditen]. Eksp Klin Farmakol. 1994 Nov-Dec;57(6):36-8. Russian. PMID: 7756958.

In vivo protocol:

Kuleshova, E. F., Anisimova, O. S., Sheinker, Y. N., Tupikina, S. M., Kaminka, M. É., Polikarpov, M. V., … Yakhontov, L. N. (1995). Study of the metabolism of the new anti-ulcer drug quiditene [(3-quinuclidyl)-di(2-thienyl)carbinol]. Pharmaceutical Chemistry Journal, 29(1), 26–29.

1: Kaminka ME, Kalinkina MA, Pushkina TV, Tupikina SM, Riabova OB, Makarov VA, Granik VG. Protivoiazvennoe deĭstvie proizvodnykh furoksapirimidina [Antiulcer activity of furoxanopyrimidine derivatives]. Eksp Klin Farmakol. 2004 May- Jun;67(3):30-3. Russian. PMID: 15341064. 2: Kaminka ME, Tupikina SM, Mashkovskiĭ MD. Eksperimental'noe issledovanie antisekretornoĭ i protivoiazvennoĭ aktivnosti kviditena [An experimental study of the antisecretory and antiulcer activities of kviditen]. Eksp Klin Farmakol. 1994 Nov-Dec;57(6):36-8. Russian. PMID: 7756958.